{"id":"oxycodone-naltrexone-capsules","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Nausea"},{"rate":"20-30%","effect":"Constipation"},{"rate":"10-20%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL656","moleculeType":"Small molecule","molecularWeight":"315.37"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Oxycodone acts as a full opioid agonist, binding to mu-opioid receptors to reduce pain perception. Naltrexone, an opioid antagonist, is included at a lower dose to block some of the euphoric effects of oxycodone, thereby reducing the potential for abuse and addiction.","oneSentence":"Oxycodone/Naltrexone capsules combine an opioid analgesic with an opioid antagonist to provide pain relief while reducing the risk of misuse and dependence.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:07.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain where the need for an opioid analgesic is required, and for which alternative treatments are inadequate"}]},"trialDetails":[{"nctId":"NCT06500793","phase":"PHASE1","title":"Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)","status":"RECRUITING","sponsor":"Ensysce Biosciences","startDate":"2024-11-24","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT05090280","phase":"PHASE1","title":"Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-12-01","conditions":"Pharmacokinetics","enrollment":111},{"nctId":"NCT01746901","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":81},{"nctId":"NCT01456507","phase":"PHASE1","title":"Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT02680847","phase":"PHASE4","title":"Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-01-21","conditions":"Moderate-severe Pain","enrollment":32},{"nctId":"NCT01775189","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT01571362","phase":"PHASE3","title":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Chronic Pain, Low Back Pain, Analgesia","enrollment":410},{"nctId":"NCT01428583","phase":"PHASE3","title":"Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Chronic Noncancer Pain","enrollment":395},{"nctId":"NCT02391571","phase":"PHASE3","title":"A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-02","conditions":"Withdrawal Symptoms","enrollment":26},{"nctId":"NCT02401750","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-06","conditions":"Pain","enrollment":163},{"nctId":"NCT02117583","phase":"PHASE1","title":"Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT02165930","phase":"PHASE1","title":"Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-07","conditions":"Healthy","enrollment":17},{"nctId":"NCT02089295","phase":"PHASE1","title":"Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT02059915","phase":"PHASE1","title":"Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":134},{"nctId":"NCT01717027","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-11","conditions":"Healthy","enrollment":19},{"nctId":"NCT01552850","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-04","conditions":"Pain","enrollment":18},{"nctId":"NCT01924676","phase":"PHASE1","title":"Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-08","conditions":"Healthy","enrollment":18},{"nctId":"NCT01552863","phase":"PHASE1","title":"A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-03","conditions":"Pain","enrollment":21},{"nctId":"NCT01557257","phase":"PHASE1","title":"Pharmacokinetics Study of ALO-02 and OxyContin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Management of Moderate to Severe Pain","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone/Naltrexone Capsules","genericName":"Oxycodone/Naltrexone Capsules","companyName":"Elite Laboratories, Inc","companyId":"elite-laboratories-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone/Naltrexone capsules combine an opioid analgesic with an opioid antagonist to provide pain relief while reducing the risk of misuse and dependence. Used for Moderate to severe chronic pain where the need for an opioid analgesic is required, and for which alternative treatments are inadequate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}